Natera (NASDAQ:NTRA) Reaches New 12-Month High – What’s Next?

Natera, Inc. (NASDAQ:NTRA)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $288.04 and last traded at $283.80, with a volume of 1358446 shares changing hands. The stock had previously closed at $279.32.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NTRA. Wolfe Research started coverage on Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Sanford C. Bernstein began coverage on shares of Natera in a research report on Friday, June 26th. They set an “outperform” rating and a $310.00 price objective for the company. The Goldman Sachs Group assumed coverage on shares of Natera in a report on Friday, June 5th. They set a “neutral” rating and a $245.00 price objective on the stock. Finally, Piper Sandler reiterated an “overweight” rating and issued a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $262.00.

Natera Trading Up 1.6%

The firm has a fifty day moving average price of $221.45 and a 200 day moving average price of $217.64. The firm has a market cap of $40.64 billion, a PE ratio of -174.11 and a beta of 1.51.

Insider Activity

In other Natera news, Director Rowan E. Chapman sold 2,964 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total value of $642,535.92. Following the transaction, the director directly owned 3,124 shares in the company, valued at $677,220.72. The trade was a 48.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00. Following the completion of the sale, the insider directly owned 134,643 shares of the company’s stock, valued at approximately $36,744,074.70. This trade represents a 2.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 178,872 shares of company stock valued at $39,627,696 in the last quarter. Insiders own 5.05% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Horizon Investments LLC raised its position in Natera by 22.0% in the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 44 shares during the period. Sound Income Strategies LLC grew its holdings in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after purchasing an additional 45 shares during the period. Savvy Advisors Inc. grew its holdings in shares of Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after purchasing an additional 46 shares during the period. Parallel Advisors LLC increased its position in shares of Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after purchasing an additional 47 shares during the last quarter. Finally, First Horizon Corp increased its position in shares of Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after purchasing an additional 51 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.